Since senescence is probably tumor-suppressive in young individuals, but potentially tumor-promoting in aged individuals, efficacious adjuvant treatment of patients using sCLU knockdown therapies (using OGX011), or exposure to IGF-1R tyrosine kinase inhibitors, may well depend on the overall age of the individual. The gene discussed is IGF1R; the disease is neoplasm.